Journal
BLOOD
Volume 104, Issue 12, Pages 3804-3812Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2004-05-1850
Keywords
-
Categories
Funding
- NCI NIH HHS [CA 102052-02] Funding Source: Medline
- NHLBI NIH HHS [R01 HL63452, HL55209, R01 HL66308, 2 R37 HL56067] Funding Source: Medline
- NIAID NIH HHS [R01 AI 34495] Funding Source: Medline
Ask authors/readers for more resources
Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after bone marrow transplantation (BMT). CD4(+)CD25(+) immune regulatory T cells (Tregs), long recognized for their critical role in induction and maintenance of self-tolerance and prevention of autoimmunity, are also important in the regulation of immune responses in allogeneic bone marrow (BM) and solid organ transplantation. Published data indicate that ex vivo activated and expanded donor Tregs result in significant inhibition of lethal nor- or host-type LSel(hi), but not LSeIlo, Tregs potently increased donor BM engraftment in sublethally irradiated mice, an event occurring independently of transforming growth factor beta signaling of host T cells. These data indicate that Treg cellular therapy warrants clinical consideration for the inhibition of GVHD and the promotion of alloengraftment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available